COO Declines Despite Q1 Earnings Beat and Raised FY26 Outlook

Core Insights - The Cooper Companies, Inc. (COO) reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of $1.10, a 19.6% increase year over year, surpassing the Zacks Consensus Estimate of $1.03 by 6.8% [2] - Revenues reached $1.02 billion, reflecting a 6% year-over-year increase on a reported basis and a 3% organic growth, aligning with the Zacks Consensus Estimate [3] - Despite strong earnings, COO's shares fell 3.6% in after-hours trading on March 5, with a 16.6% increase in the past six months compared to the industry's 21.2% rise [4] Revenue Breakdown - COO operates through two segments: CooperVision (CVI) and CooperSurgical (CSI) [5] - CVI segment revenues were $695.1 million, an 8% increase year over year on a reported basis and 3% at constant exchange rates (CER) [5] - Strong sales of MyDay and MiSight lenses contributed to CVI's growth, with MyDay lenses maintaining a double-digit growth rate [6][8] - CSI segment revenues totaled $329 million, up 3% on a reported basis, driven by strong global genomics performance [13] Geographic Performance - Americas' revenues were $289 million, up 7% year over year, driven by demand for daily silicone hydrogel lenses [11] - EMEA revenues reached $282.3 million, a 15% increase year over year, maintaining the company's leadership in the region [11] - Asia Pacific revenues fell 4% year over year to $123.8 million, primarily due to declining sales of older hydrogel lenses in Japan [12] Margin and Cost Analysis - Adjusted gross profit rose 5.3% to $697.7 million, but the adjusted gross margin contracted by nearly 100 basis points to 68% [16] - Selling, general and administrative expenses increased by 0.6% to $390.2 million, while research and development expenses rose 8.8% to $44.3 million [17] - Adjusted operating profit increased by 13.8% to $275.4 million, with the adjusted operating margin expanding by 200 basis points to 27% [17] Financial Position and Guidance - COO ended the first quarter with cash and cash equivalents of $124.9 million, up from $110.6 million at the end of the previous quarter [18] - The company raised its fiscal 2026 revenue outlook to a range of $4,306-$4,346 million, indicating an organic improvement of 4.5-5.5% from the prior year [19] - Adjusted EPS guidance for the fiscal year is now expected in the range of $4.58-$4.66, up from the previous guidance of $4.45-$4.60 [21] Future Growth Drivers - Continued expansion of premium lenses, particularly MyDay and MiSight, is expected to drive growth in the CVI segment [23] - The company is benefiting from new private-label contracts and improved commercial momentum in the Americas and EMEA [23] - Operational efficiencies from last year's reorganization and broader use of AI-driven automation are anticipated to sustain margin expansion [23]